Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma

Internal Medicine

Volumn 46, Issue 20, 2007, Pages 1723-1728

  Suzuki, Satoru ^a   Mori, Jun Ichirou ^a   Yamazaki, Masanori ^a   Sato, Ai ^a   Hosoda, Waki ^b   Hashizume, Kiyoshi ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cholangiocarcinoma; Diabetes; Pioglitazone; PPAR; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AGED; ARTICLE; AUTOPSY; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIARY TRACT DRAINAGE; CANCER INHIBITION; CASE REPORT; CHOLESTATIC HEPATITIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIABETES CONTROL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; EDEMA; HOSPITAL DISCHARGE; HUMAN; KIDNEY DYSFUNCTION; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE JAUNDICE; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; QUALITY OF LIFE; TOXIC HEPATITIS; TREATMENT REFUSAL; BILE DUCT TUMOR; DRUG ANTAGONISM; HEPATITIS; INTRAHEPATIC BILE DUCT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DIABETES MELLITUS, TYPE 2; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 35748973296     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0312     Document Type: Article

References (22)

1. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348, 2006.
2. Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17: 321-327, 2006.
3. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781, 2005.
4. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27:982-991, 2004.
5. Singh P, Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol 22: 294-299, 2006.
6. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
7. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 10: 427-432, 2004.
8. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523, 2002.
9. Rustin GJS. Circulating tumor markers. in: Oxford Textbook of Oncology. 2nd ed. Souhami RL, Tannock I, Hohenberger P, et al, Eds. Oxford University Press, New York, 2002: 303-314
10. Hisatake J-I, Ikezoe T, Carey M, et al. Down-regulation of prostate-specific antigen expregsion by ligands for peroxisome proliferators-activated receptor g in human prostate cancer. Cancer Res 60: 5494-5498, 2000.
11. Nakamura N, Aoji O, Yoshikawa T, et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Jpn J Med 25: 278-280, 1986.
12. Weng JR, Chen CY, Pinzone JJ. Beyond peroxisome proliferator activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidiones. Endocr Relat Cancer 13: 401-413, 2006.
13. Vamecq J, Latruffe N. Medical significance of peroxisome proliferators-activated receptors. Lancet 354: 141-148, 1999.
14. Kobuke T, Tazuma S, Hyogo H, Chayama K. A ligand for peroxisome proliferators-activated receptor g inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig Dis Sci 51: 1650-1657, 2006.
15. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors mi C57BL/6J-APCMin/+ mice. Nat Med 4: 1053-1057, 1998.
16. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4: 1058-1061, 1998.
17. Galli A, Mello T, Ceni E, et al. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 9: 1039-1049, 2006.
18. Jarrar MH, Banknova A. PPAR gamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGF beta, signaling. J Cell Mol Med 11: 71-87, 2007.
19. Smith MR, Manola J, Kaufman DS, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101: 1569-1574, 2004.
20. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferators-ctivated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96: 3951-3956, 1999.
21. Trappoliere M, Tuccillo C, Federico A, et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 9: 299-304, 2005.
22. Ortiz-Gonzalez J, Alvarez-Aguila NP, Medina-Castro JM. Adjust carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocrcinoma. Anticancer Res 25: 3625-3627, 2005.